## AGENDA

**Friday, October 21, 2022**

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Welcome</td>
<td>Sheetal Shroff, MD</td>
</tr>
<tr>
<td>8:10 AM</td>
<td>Overview of Myasthenia Gravis</td>
<td>Sheetal Shroff, MD</td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>9:00 AM</td>
<td>Management of Acute Exacerbations and Crisis from the Perspective of the Health Care Provider</td>
<td>Ashley Anderson, MD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>9:50 AM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:10 AM</td>
<td>Respiratory Issues in Myasthenic Disease and Management for the Non-Pulmonologists</td>
<td>Michelle Cao, MD</td>
</tr>
<tr>
<td>10:50 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Current and Future Treatments Myasthenia Gravis</td>
<td>Amanda Guidon, MD</td>
</tr>
<tr>
<td>11:50 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Adjournment</td>
<td></td>
</tr>
</tbody>
</table>

**Saturday, October 22, 2022**

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Welcome</td>
<td>Sheetal Shroff, MD</td>
</tr>
<tr>
<td>8:05 AM</td>
<td>Overview of Myasthenia Gravis</td>
<td>Sheetal Shroff, MD</td>
</tr>
<tr>
<td>8:35 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>8:45 AM</td>
<td>Management of Acute Exacerbations and Crisis</td>
<td>Ashley Anderson, MD</td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>9:25 AM</td>
<td>Navigating the ER: From the perspective of the ER physician and Neurologist</td>
<td>Amanda Guidon, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>10:10 AM</td>
<td>BREAK</td>
<td></td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Current and Future Treatments Myasthenia Gravis</td>
<td>Ericka Greene, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>11:10 AM</td>
<td>Respiratory Issues in Myasthenic Disease and Management</td>
<td>Michelle Cao, MD</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>Q &amp; A Discussion</td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Adjournment</td>
<td></td>
</tr>
</tbody>
</table>

*Click the link of the presentation to view the slides (PDF)*.

Slides are posted as they become available. Some slides may not be posted. Refresh this link to check for updates. Links not showing? We suggest trying another browser or downloading this pdf and open with a pdf viewer.
FACULTY

COURSE DIRECTORS

Ericka Green, MD, FAAN
The Sumner Family Chair in Neuromuscular Research, Stanley H. Appel Department of Neurology
Professor of Clinical Neurology, Academic Institute
Associate Clinical Member, Research Institute
Program Director, Neurology Residency and Neuromuscular Medicine Residency, Stanley H. Appel Department of Neurology
Houston Methodist
Weill Cornell Medical College

Sheetal Shroff, MD
Assistant Professor of Clinical Neurology, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College

GUEST FACULTY

Michelle Cao, MD
Neurology & Neurological Sciences Clinical Associate Professor
Psychiatry and Behavioral Sciences- Stanford Center for Sleep Sciences and Medicine

Amanda Guidon, MD
Assistant Professor of Neurology, Harvard Medical School
Program Director, Partners Neuromuscular Medicine Fellowship
Director, MGH Myasthenia Gravis Clinic
Massachusetts General Hospital

HOUSTON METHODIST FACULTY

Ashley Anderson, MD, MPH
Neuromuscular Medicine, Neurology
Neuromuscular Clinic
Houston Methodist Stanley H. Appel Department of Neurology
**Friday, October 21, 2022 – Health Care Professionals**

**PROGRAM OVERVIEW**
To familiarize health care professionals including neurologist, and non-neurologists regarding clinical presentations and evaluation of patients with acquired neuromuscular junction disorders, including myasthenia gravis, Lambert Eaton myasthenic syndrome in order to enable care providers the ability to diagnosis and manage the myasthenic patient in the acute and ambulatory care settings and minimize disease morbidity and mortality.

**TARGET AUDIENCE**
Emergency medicine physicians, ophthalmologists, internal medicine, pulmonologist, general neurologist, neuromuscular neurologists, anesthesiologists, RN, NPs, PA’s and allied health professionals (RT’s, Speech therapists, Social work, EMT)

**EDUCATIONAL OBJECTIVES**
At the conclusion of this activity, the participant should be able to:
- Explain the clinical presentations and progression of myasthenic syndromes and associated comorbidities
- Discuss current and emerging therapies for the symptomatic and disease treatment of these disorders
- Describe emerging therapies and research outcomes for these and related disorders
- Apply a working algorithm to facilitate more effective management of the patient

**NURSING OUTCOMES STATEMENT**
Nurses attending this activity will be able to describe clinical signs and symptoms and apply this to nurse decision-making related to the care of the myasthenia Gravis patient as evidenced by a self-reported change in practice on the program evaluation and declaration of at least one learning He/she will apply to their practice.

**EDUCATION METHODS**
Didactic lectures, panel discussion

**EVALUATION METHOD**
Evaluation by questionnaire will address program content, presentation, and possible bias.

---

**Saturday, October 22, 2022 – Patients and Caregivers**

**PROGRAM OVERVIEW**
To provide an overview of acquired autoimmune myasthenia gravis to affected patients, patient family and care providers in order to provide patient ability to self-advocate for appropriate treatment and management by their health care professionals and within the system of medicine and research. In addition, the conference is to provide an opportunity for networking among patients for community support and formal advocacy.

**TARGET AUDIENCE**
Patients with MG, family members, care providers, friends of MG patients. Allied health professionals including SW, RT, OT, PT, speech therapy.

**EDUCATIONAL OBJECTIVES**
At the conclusion of this activity, the participant should be able to:
- Explain the clinical presentations and progression of myasthenia gravis and associated comorbidities
- Discuss current therapies for the symptomatic and disease treatment of these disorders
- Describe emerging therapies and research outcomes for these disorders
• Discuss the respiratory evaluation and management of myasthenia gravis and provide recommendations to effectively access appropriate medical care in the acute setting
• Provide opportunity for networking and exchange of information among patients and promote advocacy within the MG patient community

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 3.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *

Nurses
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Houston Methodist will provide up to 3.67 contact hours for this activity. Participants must attend each session in its entirety and complete the corresponding items on the evaluation tool. *

Respiratory Care
This activity has been approved for 3.41 CEUs pending approval by the American Association for Respiratory Care. *

Physical Therapists/Physical Therapist Assistants
This activity has been approved by the Texas Board of Physical Therapy Examiners for 7.0 total CCUs for PTs and PTAs if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

Occupational Therapists
This activity has been approved for 7.0 hours of OT Education by The Texas Board of Occupational Therapy Examiners if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

Speech-Language Pathologists
This program has been approved for 7.0 clock hours of continuing education credit by the Texas Speech-Language Hearing Association (TSHA) if attendance is recorded both days. Friday CCUs total 3.5. Saturday CCUs total 3.5.

Social Workers
Houston Methodist designates this activity for 3.5 CEUs for the first day, 3.5 CEUs for the second day, and a total 7.0 CEUs if attended both days for social work. This offering complies with section 781.509 of the rules of The Texas State Board of Social Work Examiners www.bhec.texas.gov

*CE credits for CME, CNE and RT will only be awarded for attending the Health Care Professionals Day Conference on Friday, October 21, 2022.

HOW TO RECEIVE YOUR CERTIFICATE

Physicians
An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.
13th Annual Myasthenia Gravis Conference for the Neurologist and Non-Neurologist Care Provider
Hybrid Symposium
Friday, October 21 – Saturday, October 22, 2022

Nurses
To be awarded up to 3.67 contact hours for this continuing education activity, the participant must:
  o Be sure to check in and complete the sign in process
  o Attend each session in its entirety (Contact hours are awarded only for full day attendance)
  o Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

Respiratory Care
Radiologic Technologists must sign in and attend each session in its entirety. Partial credit will not be awarded.

DISCLAIMER AND DISCLOSURES
Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All the relevant financial relationships listed for these individuals have been mitigated.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Relevant Financial Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Anderson, MD, MPH</td>
<td>Speaker</td>
<td>Speaker: Argenx</td>
</tr>
<tr>
<td>Amanda Guidon, MD, MPH</td>
<td>Speaker</td>
<td>Consultant: UCB; Consultant: Alexion; Consultant: Argenx; Consultant: Biosensics; Speaker: Oakstone; Researcher: Project Data Sphere</td>
</tr>
<tr>
<td>Sheetal Shroff, MD</td>
<td>Co-Director/ Speaker</td>
<td>Consultant: Alnylam</td>
</tr>
</tbody>
</table>

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.
EXHIBITORS
We gratefully acknowledge the following companies for participating as exhibitors at this activity:

Accredo
Alexion
Argenx
Immunovant
UCB